Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
None
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

  • 0 views
  • 28 May, 2021
  • 1 location
None
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

oophorectomy
cancer of the ovary
cancer
rad51c
ovarian cancer
  • 0 views
  • 09 Oct, 2021
  • 14 locations
None
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their …

genetic testing
triple negative breast cancer
estrogen receptor
breast cancer
epidermal growth factor receptor
  • 24 views
  • 23 Jan, 2021
  • 5 locations
None
COsegregation of VARiants in Panel of Genes

The aim of the COVAR project is to classify reliably a maximum of VUS of the French database in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some …

breast cancer
cancer of the ovary
KIT
BRCA1/2
cancer
  • 16 views
  • 09 Aug, 2021
  • 86 locations
None
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF

platelet count
serum pregnancy test
metastatic renal cell carcinoma
CHEK2
RAD54L
  • 19 views
  • 21 Mar, 2021
  • 1 location
None
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking …

prostatectomy
platelet count
niraparib
tumor cells
bone scan
  • 6 views
  • 15 Apr, 2021
  • 1 location
None
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond …

cytotoxic chemotherapy
platelet count
bone marrow infiltration
cns neoplasm
cancer treatment
  • 219 views
  • 22 Dec, 2021
  • 76 locations
None
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative breast cancer are eligible.

platelet count
serum pregnancy test
PTEN
estrogen receptor
solid tumour
  • 5 views
  • 08 Sep, 2021
  • 1 location
None
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy With Integrated Biomarker Analysis

Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a radiographic response also had a PSA5 response. Ten of 11 responders had mutations in DNA repair genes. While …

prostatectomy
platelet count
absolute neutrophil count
prostate adenocarcinoma
androgens
  • 8 views
  • 16 Jun, 2021
  • 4 locations
None
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CYH33 in combination with olaprib in patients with DDR gene mutations and/or PIK3CA mutations, in patients who have progressed on prior PARP inhibitor, and in patients with recurrent high grade serous ovarian, fallopian tube, or …

parp inhibitor
cancer
peritoneal cancer
cancer antigen 125
PIK3CA
  • 5 views
  • 19 Feb, 2021
  • 1 location